708 related articles for article (PubMed ID: 15754342)
21. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
[TBL] [Abstract][Full Text] [Related]
22. Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095).
Sotomayor S; Muñoz-Moreno L; Carmena MJ; Schally AV; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Cancer; 2010 Oct; 127(8):1813-22. PubMed ID: 20099275
[TBL] [Abstract][Full Text] [Related]
23. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Busto R; Halmos G
J Clin Endocrinol Metab; 2001 May; 86(5):2144-52. PubMed ID: 11344219
[TBL] [Abstract][Full Text] [Related]
24. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes.
Bajo AM; Schally AV; Krupa M; Hebert F; Groot K; Szepeshazi K
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3836-41. PubMed ID: 11891317
[TBL] [Abstract][Full Text] [Related]
25. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells.
Levine L; Lucci JA; Pazdrak B; Cheng JZ; Guo YS; Townsend CM; Hellmich MR
Cancer Res; 2003 Jul; 63(13):3495-502. PubMed ID: 12839933
[TBL] [Abstract][Full Text] [Related]
26. Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone.
Keller G; Schally AV; Groot K; Toller GL; Havt A; Köster F; Armatis P; Halmos G; Zarandi M; Varga JL; Engel JB
Proc Natl Acad Sci U S A; 2005 Jul; 102(30):10628-33. PubMed ID: 16027368
[TBL] [Abstract][Full Text] [Related]
27. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
Klukovits A; Schally AV; Szalontay L; Vidaurre I; Papadia A; Zarandi M; Varga JL; Block NL; Halmos G
Cancer; 2012 Feb; 118(3):670-80. PubMed ID: 21751186
[TBL] [Abstract][Full Text] [Related]
28. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
[TBL] [Abstract][Full Text] [Related]
29. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
Halmos G; Schally AV
Proc Natl Acad Sci U S A; 1997 Feb; 94(3):956-60. PubMed ID: 9023364
[TBL] [Abstract][Full Text] [Related]
30. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Pinski J; Halmos G; Szepeshazi K; Schally AV
Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
[TBL] [Abstract][Full Text] [Related]
31. A potent bombesin receptor antagonist inhibits bombesin-stimulated growth of mouse colon cancer cells in vitro: absence of autocrine effects.
Narayan S; Spindel ER; Rubin NH; Singh P
Cell Growth Differ; 1992 Feb; 3(2):111-8. PubMed ID: 1323998
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
33. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
34. Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.
Szereday Z; Schally AV; Varga JL; Kanashiro CA; Hebert F; Armatis P; Groot K; Szepeshazi K; Halmos G; Busto R
Cancer Res; 2003 Nov; 63(22):7913-9. PubMed ID: 14633721
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
Chatzistamou I; Schally AV; Szepeshazi K; Groot K; Hebert F; Arencibia JM
Cancer Lett; 2001 Sep; 171(1):37-45. PubMed ID: 11485826
[TBL] [Abstract][Full Text] [Related]
36. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.
Szepeshazi K; Schally AV; Groot K; Armatis P; Halmos G; Herbert F; Szende B; Varga JL; Zarandi M
Br J Cancer; 2000 May; 82(10):1724-31. PubMed ID: 10817510
[TBL] [Abstract][Full Text] [Related]
37. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
Papadia A; Schally AV; Halmos G; Varga JL; Seitz S; Buchholz S; Rick F; Zarandi M; Bellyei S; Treszl A; Szalontay L; Lucci JA
Horm Metab Res; 2011 Oct; 43(11):816-20. PubMed ID: 22009378
[TBL] [Abstract][Full Text] [Related]
38. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer.
Schally AV; Varga JL; Engel JB
Nat Clin Pract Endocrinol Metab; 2008 Jan; 4(1):33-43. PubMed ID: 18084344
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
Engel JB; Keller G; Schally AV; Toller GL; Groot K; Havt A; Armatis P; Zarandi M; Varga JL; Halmos G
J Clin Endocrinol Metab; 2005 Jun; 90(6):3614-21. PubMed ID: 15784701
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
Milovanovic SR; Radulovic S; Groot K; Schally AV
Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
